Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ME-344 + bevacizumab
- Development stage
- Phase 1
- Lead developer
- MEI Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
ME-344 + bevacizumab is a combination therapy consisting of ME-344, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor, and bevacizumab (Avastin), an anti-angiogenic antibody. This combination creates metabolic synthetic lethality by leveraging the ability of bevacizumab to reduce glycolysis, forcing tumors to switch to mitochondrial respiration via OXPHOS, which is then inhibited by ME-344. The combination has shown promising results in clinical trials for metastatic colorectal cancer and HER2-negative breast cancer.
02
Targets
ND1 (Mitochondrial electron transport chain complex I)SDH (Mitochondrial electron transport chain complex II)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ME-344 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ME-344 + bevacizumab.